Literature DB >> 2568767

Dose-response relationships for edrophonium and neostigmine as antagonists of atracurium and vecuronium neuromuscular blockade.

C E Smith1, F Donati, D R Bevan.   

Abstract

To determine the potencies of edrophonium and neostigmine as antagonists of nondepolarizing neuromuscular blockade produced by atracurium and vecuronium, dose-response curves were constructed for both antagonists when given at 10% spontaneous recovery of first twitch height. Ninety ASA physical status 1 and 2 adults were given either 0.4 mg/kg atracurium or 0.08 mg/kg vecuronium during thiopental-nitrous oxide-enflurane anesthesia. Train-of-four stimulation was applied to the ulnar nerve every 12 s, and the force of contraction of the adductor pollicis muscle was recorded. When spontaneous recovery of first twitch height reached 10% of its initial control value, edrophonium (0.1, 0.2, 0.4, or 1 mg/kg) or neostigmine (0.005, 0.01, 0.02, or 0.05 mg/kg) was administered by random allocation. Neuromuscular function in another ten subjects was allowed to recover spontaneously. Assisted recovery was defined as actual recovery minus mean spontaneous recovery observed in patients who were not given antagonists. First twitch recovery was initially more rapid when vecuronium was antagonized compared with atracurium, but no difference was detected after 10 min. At 10 min the neostigmine ED80 was 0.022 +/- 0.003 (SEM) mg/kg after atracurium and 0.024 +/- 0.003 mg/kg after vecuronium. The edrophonium ED80 was 0.44 +/- 0.11 mg/kg with atracurium and 0.46 +/- 0.12 mg/kg with vecuronium, giving a neostigmine:edrophonium potency ratio of 20. Atracurium train-of-four fade could be antagonized more easily with edrophonium, whereas that of vecuronium was more easily antagonized by neostigmine. It is concluded that edrophonium and neostigmine are not equally effective against atracurium and vecuronium.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568767     DOI: 10.1097/00000542-198907000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

Review 1.  Monitoring, new drugs, and reversal of neuromuscular blocking drugs.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

2.  Edrophonium antagonism of vecuronium at varying degrees of fourth twitch recovery.

Authors:  Y M Salib; F Donati; D R Bevan
Journal:  Can J Anaesth       Date:  1993-09       Impact factor: 5.063

3.  Sevoflurane and isoflurane impair edrophonium reversal of vecuronium-induced neuromuscular block.

Authors:  T Morita; D Kurosaki; H Tsukagoshi; T Sugaya; S Saito; H Sato; T Fujita
Journal:  Can J Anaesth       Date:  1996-08       Impact factor: 5.063

4.  Neostigmine and edrophonium for reversal of pipecuronium neuromuscular blockade.

Authors:  M Abdulatif; M Naguib
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

5.  Continuous infusions of atracurium and vecuronium, compared with intermittent boluses of pancuronium: dose requirements and reversal.

Authors:  W S Beattie; D N Buckley; J B Forrest
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

6.  Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.

Authors:  A Sidi; R F Kaplan; R F Davis
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

7.  Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial.

Authors:  Satyen Parida; Venkatesan Kausalya; Sandeep Kumar Mishra; Sethuramachandran Adinarayanan
Journal:  Indian J Anaesth       Date:  2017-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.